"A" is for amylin and amyloid in type 2 diabetes mellitus

Journal of the Pancreas

Volumn 2, Issue 4, 2001, Pages 124-139

  Hayden, Melvin R ^a,b   Tyagi, Suresh C ^c  

^a Camdenton Community Health Center   (United States)

^b UNIVERSITY OF MISSOURI   (United States)

^c UNIVERSITY OF MISSISSIPPI MEDICAL CENTER   (United States)

Author keywords

Amyloid; Apoptosis; Diabetes mellitus, non insulin dependent; Glucose (toxicity); Insulin; Insulin resistance; Islet of Langerhans; Oxidation reduction; Pancreas; Pancreatic polypeptide; Reactive oxygen species

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALPHA GLUCOSIDASE INHIBITOR; AMYLIN; AMYLIN DERIVATIVE; AMYLOID; AMYLOID P COMPONENT; ANGIOTENSIN 1 RECEPTOR; ANTIHYPERTENSIVE AGENT; ANTIOXIDANT; APOLIPOPROTEIN E; C REACTIVE PROTEIN; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; GLIBENCLAMIDE; GLUCOSE; GLYCOSAMINOGLYCAN; HEMOGLOBIN A1C; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; MEGLITINIDE; METFORMIN; PERLECAN; PRAMLINTIDE; PRAVASTATIN; REACTIVE OXYGEN METABOLITE; SERUM AMYLOID A; SERUM AMYLOID P; THYROID EXTRACT; UNINDEXED DRUG;

BASEMENT MEMBRANE; CAPILLARY ENDOTHELIUM; CELL DAMAGE; CLINICAL TRIAL; DATA ANALYSIS; DEMENTIA; DRUG MECHANISM; EARLY DIAGNOSIS; HUMAN; INSULIN DEFICIENCY; INSULIN RELEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OXIDATION REDUCTION REACTION; OXIDATIVE STRESS; PANCREAS ISLET; PANCREAS ISLET BETA CELL; PHENOMENOLOGY; PROTEIN FOLDING; PROTEIN FUNCTION; PROTEIN SECONDARY STRUCTURE; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK REDUCTION; TREATMENT PLANNING; AMINO ACID SEQUENCE; CHEMISTRY; CLASSIFICATION; METABOLISM; MOLECULAR GENETICS; PATHOLOGY; PHYSIOLOGY; ULTRASTRUCTURE;

AMINO ACID SEQUENCE; AMYLOID; DIABETES MELLITUS, TYPE 2; HUMANS; MOLECULAR SEQUENCE DATA;

EID: 0035411025     PISSN: 15908577     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (83)

1. Opie EL. The relation of diabetes mellitus to lesions of the pancreas: hyaline degeneration of the islands of Langerhans. J Exp Med 1901; 5:527-40.
2. Bliss M. The Discovery of Insulin. Chicago, IL, USA: The University of Chicago Press, 1982: 60637.
3. Ahronheim JH. Nature of hyaline material in pancreatic islets in diabetes mellitus. Am J Pathol 1943; 19:873-82.
4. Ehrlich JC, Ratner IM. Amyloidosis of the islets of Langerhans. A restudy of islet hyaline in diabetic and non diabetic individuals. Am J Pathol 1961; 38:49-59.
5. Westermark P. Fine structure of islets of Langerhans in insular amyloidosis. Virchows Arch A Pathol Anat 1973; 359:1-18.
6. Westermark P, Wernstedt C. Islet amyloid in type 2 human diabetes mellitus and adult diabetic cats contain a novel putative polypeptide hormone. Am J Pathol 1987; 127:414-7.
7. Cooper GJS, Willis AC. Purification and characterization of a peptide from amyloid-rich pancreas of type 2 diabetic patients. Proc Natl Acad Sci USA 1987; 84:8628-32.
8. Hayden MR, Tyagi SC. Remodeling of the endocrine pancreas: The central role of amylin and insulin resistance. South Med J 2000; 93:24-8. [20116761]
9. Gregg EW, Narayan Venkat KM. Type 2 diabetes and cognitive function: Are cognitive impairment and dementia complications of type 2 diabetes? Clin Geriatr 2000; 8:57-72.
10. Kisilevsky R. Amyloids: Tombstones or Triggers. Nature 2000; 6:633-4.
11. Clark A, Charge SB, Badman MK, de Koning EJ. Islet amyloid in type 2 (non-insulin-dependent) diabetes. APMIS 1996: 104:12-8. [96194271]
12. Clark A, Saas MF, Nezzer T, Uren C, Knowler WC, Bennett PH, Turner RC. Islet amyloid polypeptide in diabetic and non-diabetic Pima Indians. Diabetologia 1990; 33:285-9.
13. Cooper GJS, Leighton B, Dimitriadis GD, Parry-Billings M, Kowalchuk JM, Howland K, et al. Amylin found in amyloid deposits in human type 2 diabetes mellitus may be a hormone that regulates glycogen metabolism in skeletal muscle. Proc Natl Acad Sci USA 1988; 85:7763-6. [89017278]
14. Nisi M, Sanke T, Seino S, Eddy RL, Fan YS, Byers MG, et al. Human islet amyloid polypeptide gene: complete nucleotide sequence, chromosomal localization, and evolutionary history. Mol Endocrinol 1989; 3:1775-81. [90114181]
15. Badman MK, Shennan KI, Jermany JL, Docherty K, Clark A. Processing of pro-islet amyloid polypeptide (proIAPP) by the prohormone convertase PC2. FEBS Lett 1996; 378:227-31.
16. Ludvik B, Kautzky-Willer, Prager R, Thomaseth K, Pacini G. Amylin: History and Overview. Diabetes Medicine 1997; 14(Suppl 2): S9-13.
17. Lutz TA, Althaus J, Rossi R, Scharrer E. Anorectic effect of amylin is not transmitted by capsaicin-sensitive nerve fibers. Am J Physiol 1998; 274: R1777-82.
18. Lutz TA, Rossi R, Althaus J, Del Prete E, Scharrer E. Amylin reduces food intake more potently than calcitonin gene-related peptide (CGRP) when injected into the lateral brain ventricle in rats. Peptides 1998; 19: 1533-40.
19. ArneloU, Permert J, Adrian TE, Larsson J, Westermark P. Chronic infusion of islet amyloid polypeptide causes anorexia in rats. Am J Physiol 1996; 271: R1654-9.
20. Riediger T, Schmid HA, Young AA, Simon E. Pharmacological characterization of amylin-related peptides activating subfornical organ neurones. Brain Res 1999; 837:161-8.
21. Wookey PJ, Tikellis C, Du HC, Qin HF, Sexton PM, Cooper ME. Amylin binding in rat renal cortex, stimulation of adenylyl cyclase, and activation of plasma renin. Am J Physiol 1996; 270:F289-94.
22. Cooper ME, McNally PG, Phillips PA, Johnston CI. Amylin stimulates plasma renin concentration in humans. Hypertension 1995; 26:460-4.
23. USAN council. List No.392. New names. Amlintide. Clin Pharmacol Ther. 1997; 61:500.
24. Young AA, Jodka CM, Green DE, Gedulin BR. Inhibition of arginine-induced glucagon secretion by amylin in rats. Diabetes 1994; 44:238A.
25. Young AA, Gedulin B Rink TJ. Dose-responses for the slowing of gastric emptying in a rodent model by glucagons-like peptide (7-36)NH2, amylin, cholecystokinin, and other possible regulators of nutrient uptake. Metabolism 1996; 45:1-3.
26. Fox N, Schrementi J, Nishi M, Ohagi S, Chan SJ, Heisserman JA, et al. Human islet amyloid polypeptide transgenic mice as a model of non-insulin-dependent diabetes mellitus (NIDDM). FEBS Lett 1993; 323:40-4. [93265940]
27. D'Alessio DA, Verchere CB, Kahn SE, Hoagland V, Baskin DG, Palmiter RD, Ensinck JW. Pancreatic expression and secretion of human islet amyloid polypeptide in a transgenic mouse. Diabetes 1994; 43:1457-61. [95046959]
28. Yagui K, Yamaguchi T, Kanatsuka A, Shimada F, Huang CI, Tokuyama Y, et al. Formation of islet amyloid fibrils in beta-secretory granules of transgenic mice expressing human islet amyloid polypeptide / amylin. Eur J Endocrinol 1995;132:487-96. [95227347]
29. Janson J, Soeller WC, Roche PC, Nelson RT, Torchia AJ, Kreutter DK, Butler PC. Spontaneous diabetes mellitus in transgenic mice expressing human islet amyloid polypeptide. Proc Natl Acad Sci USA 1996; 92: 7283-7288. [96293516]
30. Westermark G, Benig-Arora M, Fox N, Carroll R, Chan SJ, Westermark P, Steiner DF. Amyloid formation in response to beta cell stress in vitro, but not in vivo, in islets of transgenic mice expressing human islet amyloid polypeptide. Mol Med 1995; 1:542-53.
31. Janson J, Ashley RH, Harrison D, McIntyre S, Butler PC. The mechanism of islet amyloid polypeptide toxicity is membrane disruption by intermediate-sized toxic amyloid particles. Diabetes 1999; 48:491-8. [99176434]
32. Jones LC, Clark A. beta cell neogenesis in type 2 diabetes mellitus. Diabetes 2001; 50(Suppl 1):S186-7. [21088715]
33. Guiot Y, Sempoux C, Moulin P, Rahier J. No decrease of the beta cell mass in type 2 patients. Diabetes 2001; 50(Suppl 1):S188. [21088716]
34. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes(UDPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352:837-53. [98413908]
35. Howard CE Jr, Van Bueren A. Changes in islet cell composition during development of diabetes in Macaca Nigra. Diabetes 1986; 35:165-71.
36. Hisaoke M, Haratake J, Yamamoto O, Horie A. Three-dimensional observation of the rat endocrine pancreas by a scanning electron microscope. J UOEH 1990; 12:315-22. [91047347]
37. Murakami T, Fujita T. Microcirculation of the rat pancreas, with special reference to the insulo-acinar portal and insulo-venous drainage systems: a further scanning electron microscope study of corrosion casts. Arch Histol Cytol 1992; 55:453-76. [93199848]
38. Williamson JR, Kilo C. Hyperglycemia "Pseudohypoxia" and diabetic complications. Diabetes 1993; 42:801-13.
39. Messerli FH, Grossman E. CAPPP trial. Captopril Prevention Project. Lancet 1999; 353:1795-6.
40. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-convertingenzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000; 342:145-53. [20092358]
41. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: Results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. Lancet 2000; 355:253-9. [20137536]
42. Tahmasebi M. Puddefoot JR, Inwang ER, Vinson GP. The tissue rennin angiotensin system in human pancreas. J Endocrinol 1999; 161:317-22.
43. Nickenig G, Roling J, Strehlow K, Schnabel P, Bohm M. Insulin induces upregulation of vascular AT-1 receptor gene expression by posttranscriptional mechanisms. Circulation 1998; 98:2453-60. [99051528]
44. Cooper ME, McNally PG. Amylin stimulates plasma rennin concentration in humans. Hypertension 1995; 26:460-4.
45. Carlsson PO. The renin-angiotensin system in the endocrine pancreas. JOP. J Pancreas (Online) 2001; 2:26-32.
46. Freeman DJ, Norrie J, Sattar N, Neely RD, Cobbe SM, Ford I, et al. Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study. Circulation 2001; 103:357-62. [21112837]
47. Mujumdar V, Hayden MR, Tyagi SC. Homocyst(e)ine induces calcium second messenger in vascular smooth muscle cells. J Cell Physiol 2000; 183:28-36. [20164640]
48. Jick H, Zornberg GL, Jick SS Seshadri S, Drachman DA. Statins and the risk of dementia. Lancet 2000; 356:1627-31.
49. Wolozin B, Keilman W, Ruosseau P, Celesia GG, Siegel G. Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Arch Neurol 2000; 57:1410-43.
50. Guo Z, Fratiglioni L, Vitanen M, Lannfelt L, Basun H, Fastbom J, Winblad B. Apolipoprotein E genotypes and the incidence of Alzheimer's disease among persons aged 75 years and older. Variation by use of antihypertensive medication. Am J Epidemiol 2001; 153;225-31.
51. Desouza C, Fonseca VA. Insulin sensitizer combination therapy for type 2 diabetes. Cardiology Review 2001; 18:11-5.
52. Fonseca V, Rosenstock J, Patwardhan R, Salzman A. Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial. JAMA 2000; 283:1695-702. [20216271]
53. Fuchtenbusch M, Standl E, Schatz H. Clinical efficacy of new thiazolidinediones and glinides in the treatment of type 2 diabetes mellitus. Exp Clin Endocrinol Diabetes 2000; 108:151-63.
54. Mooradian AD, Albert SG, Bernbaum M, Plummer S. The effect of glipizide gastrointestinal therapeutic system on islet cell hormonal responses to a test meal in NIDDM. Diabetes Care 1996; 19:883-4.
55. Dunn CJ, Faulds D. Nateglinide. Drugs 2000; 60:607-15.
56. Horton ES, Clinkingbeard C, Gatlin M, Foley J, Mallows S Shen S. Nateglinide alone and in combination with metformin improves glycemic control by reducing mealtime glucose levels in type 2 diabetes. Diabetes Care 2000; 23:1660-5.
57. Ikenoue T, Kondo N. Pharmacological properties of Nateglinide, repid-onset/short-duration insulinotropic agent, in the treatment of type 2 diabetes. Nippon Yakurigaku Zasshi 2000; 116:171-80.
58. Hayden MR, Tyagi SC. Arterial vascular remodeling: The endothelial cell's central role. Mo Med 1998; 95:213-7. [98268026]
59. Hayden MR, Tyagi SC. Atherosclerosis: implications of angiotensin II and the AT-1 receptor. Chapter 18: In: Dhalla NS, Zahradka P, Dixon IMC, Beamish RE, eds. Angiotensin II Receptor Blockade: Physiological and Clinical Implications. Norwell, Mass, USA: Kluwer Academic Publishers, 1998: 233-243.
60. Pinhas-Hamiel O, Zeitler P. Type 2 diabetes: Not just for grownups anymore. Contemp Pediatr 2001; 18:102-25.
61. Zieske AW, Malcom GT, Strong JP. Pathobiological determinants of atherosclerosis in youth (PDAY) cardiovascular specimen and data library. J La State Med Soc 2000; 152:296-301. [20391055]
62. McGill HC, McMahan CA, Herderick EE, Tracy RE, Malcom GT, Zieske AW, Strong JP. Effects of coronary heart disease risk factors on atherosclerosis of selected regions of the aorta and right coronary artery. PDAY Research Group. Pathobiological Determinants of Atherosclerosis in Youth. Arterioscler Thromb Vasc Biol 2000; 20:836-45.
63. McGill HC, McMahan CA, Herderick EE, Tracy RE, Malcom GT, Zieske AW, Strong JP. Effects of coronary heart disease risk factors on atherosclerosis of selected regions of the aorta and right coronary artery. PDAY Research Group. Pathobiological Determinants of Atherosclerosis in Youth. Arterioscler Thromb Vasc Biol 2000; 20:1998-2004.
64. Pinhas-Hamiel O, Dolan LM, Daniels SR, Standiford D, Khoury PR, Zeitler P. Increasing incidence of non-insulin-dependent diabetes mellitus in children and adolescents. J Pediatr 1996; 128:608.
65. Pinhas-Hamiel O, Standford D, Daniels SR, et al. A persistent increase of noninsulin-dependent diabetes mellitus (NIDDM) among adolescents. Int J Obesity 1998; 206 (Suppl 3):414.
66. Soto C, Sigurdsson EM, Morelli L, Kumar RA, Castano EM, Frangione B. Beta-sheet breaker peptides inhibit fibrillogenesis in a rat brain model of amyloidosis: implications for Alzheimer's therapy. Nat Med 1998; 4:822-6.
67. Kenny SJ, Aubert RE, Geiss LS. Prevalence and incidence of non-insulin dependent diabetes. National Diabetes Data Group (US). In: Harris M, ed. Diabetes in America. 2nd ed. NIH Publication No. 95-1468. Bethesda, MD, USA: National Institutes of Health, National Institutes of Diabetes and Digestive and Kidney Diseases, 1995: 47-68.
68. Seshaiah V. An interview with Reuters Health Information Services. (A Medical News Service on Physicians Online). In: Sanjay Kumar, ed. Annual Conference of the Association of Physicians of India. 2001.
69. Maloy AL, Longnecker DS, Greenbery ER. The relation of islet amyloid to the clinical type of diabetes. Hum Pathol 1981; 12: 917-22.
70. Ohsawa H, Kanatsuka A, Mizuno Y, Tokuyama Y, Takada K, Mikata A, et al. Islet amyloid polypeptide-derived amyloid deposition increases along with the duration of type 2 diabetes mellitus. Diabetes Res Clin Pract 1992; 15:17-21.
71. Rocken C, Linke RP, Saeger W. Immunohistology of islet amyloid polypeptide in diabetes mellitus: Semiquantitative studies in a post-mortem series. Virchows Arch A Pathol Anat Histopathol 1992; 421:339-44.
72. Hoenig M, Hall G, Ferguson D, Jordan K, Henson M, Johnson K, O'Brien T. A feline model of experimentally induced islet amyloidosis. Am J Pathol 2000; 157:2143-50.
73. O'Brien TD, Johnson KH, Hayden DW. Pancreatic ganglioneuronal amyloid. Occurrence in diabetic cats with islet amyloidosis. Am J Pathol 1985; 119:430-5.
74. Ma Z, Westermark GT, Johnson KH, O'Brien TD, Westermark P. Quantitative immunohistochemical analysis of islet amyloid polypeptide (IAPP) in normal, impaired glucose tolerant, and diabetic cats. Amyloid 1998; 5:255-61.
75. Yano BL, Hayden DW, Johnson KH, Feline insular amyloid: Incidence in adult cats with no clinicopathologic evidence of overt diabetes mellitus. Vet Pathol 1981; 18:310-5.
76. Johnson KH, O'Brien TD, Jordan K, Betsholtz C, Westermark P. The putative hormone islet amyloid polypeptide (IAPP) induces impaired glucose tolerance in cats. Biochem Biophys Res Commun 1990; 167:507-13.
77. Yano BL, Hayden DW, Johnson KH, Feline insular amyloid: association with diabetes mellitus. Vet Pathol 1981; 18:621-7.
78. Lutz TA, Rand JS. A review of new developments in type 2 diabetes in human beings and cats. Br Vet J 1993; 149:527-36.
79. Lutz TA, Rand JS. Pathogenesis of feline diabetes mellitus. Vet Clin North Am Small Anim Pract 1995; 25:527-52.
80. Tuomilehto J, Qiao Q, Balkau B, Borch-Johnson K. Glucose tolerance and all-cause mortality. Cardiology Rev 2001; 18:241-53.
81. Kahn SE, Andrikopoulos S, Verchere CB. Islet Amyloid A long-recognized but underappreciated pathological feature of type 2 diabetes. Diabetes 1999; 48:241-53. [99265466]
82. Hoppener JW, Ahren B, Lips CJ. Islet amyloid and type 2 diabetes mellitus. N Eng J Med 2000; 343:411-9. [20373846]
83. Westermark GT, Westermark P. Endocrine amyloid - a subject of increasing interest for the next century. Amyloid. 2000; 7:19-22.